All In Biotech

Drug Trial Radar · NCT00879658

Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

A Phase II, Double-blind, Randomized, Multi-center, Adaptive Dose-ranging, Placebo-controlled, Parallel-group Study Evaluating Safety, Tolerability and Efficacy on MRI Lesion Parameters and Determining the Dose Response Curve of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis.

Last checked: Nov 20, 2026Latest source record: Jan 13, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 297 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

297

Actual

Start

Mar 30, 2009

Primary completion

May 4, 2011

Study completion May 4, 2011

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 10, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and tolerability for the selection of an optimal dose in a later phase III study. Study Design Rationale An adaptive design was chosen to characterize the dose response curve of BAF312. In a first period of study ("Period 1"), three doses of BAF312 and placebo were tested for MRI efficacy. Based on an interim analysis (IA) after 3 months of treatment, two additional active doses for period 2 wereselected , thus allowing to optimize the overall determination of the dose response curve with 5 data points of active treatment, and placebo. The doses were kept blinded. The use of Modeling and Simulation allowed to establish the full range and dynamics of the dose-response curve in silico, and hence the definition of the optimal dose for later phase III studies. The choice of placebo as treatment control was essential to obtain information on the specific compared to non-specific effects of active treatment and provides the best way of evaluating the efficacy and of assessing the true safety and tolerability profile of BAF312. Short-term placebo exposure (6 (Period 1) or 3 (Period 2) months, respectively) was unlikely to lead to longer term differences in outcomes \[Polman, 2008\]. The use of an adaptive design strategy contributed to a significant reduction of placebo exposure, both in terms of the number of patients and duration, as compared to conventional trial models. Patients having completed the study within the protocol might be eligible for the Extension Phase study where they receive long-term BAF312 treatment (a separate protocol).

Conditions

  • Relapsing-remitting Multiple Sclerosis

Interventions

  • BAF312Drug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Responsiveness of BAF312 Based on the Number of Combined Unique Active MRI Lesions (CUAL)Time frame: 3 months of treatment

Locations

72 sites in 12 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Cullman, Alabama

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Centennial, Colorado

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Pompano Beach, Florida

  • Novartis Investigative Site

    Tallahassee, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Elk Grove Village, Illinois

  • Novartis Investigative Site

    Grand Rapids, Michigan

  • Novartis Investigative Site

    Raleigh, North Carolina

  • Novartis Investigative Site

    Akron, Ohio

  • Novartis Investigative Site

    Pittsburgh, Pennsylvania

  • Novartis Investigative Site

    Greenville, South Carolina

  • Novartis Investigative Site

    Seattle, Washington

  • Novartis Investigative Site

    Milwaukee, Wisconsin

  • Novartis Investigative Site

    Vancouver, British Columbia, Canada

  • Novartis Investigative Site

    Ottawa, Ontario, Canada

  • Novartis Investigative Site

    Gatineau, Quebec, Canada

  • Novartis Investigative Site

    Greenfield Park, Quebec, Canada

  • Novartis Investigative Site

    Montreal, Quebec, Canada

  • Novartis Investigative Site

    Helsinki, Finland

  • Novartis Investigative Site

    Tampere, Finland

  • Novartis Investigative Site

    Turku, Finland

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Dresden, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Leipzig, Germany

  • Novartis Investigative Site

    Lengerich, Germany

  • Novartis Investigative Site

    München, Germany

  • Novartis Investigative Site

    Münster, Germany

  • Novartis Investigative Site

    Wiesbaden, Germany

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Budapest, Hungary

  • Novartis Investigative Site

    Debrecen, Hungary

  • Novartis Investigative Site

    Veszprém, Hungary

  • Novartis Investigative Site

    Montichiari, BS, Italy

  • Novartis Investigative Site

    Chieti, CH, Italy

  • Novartis Investigative Site

    Milan, MI, Italy

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.